Andreas Struengmann & family

Andreas Struengmann & family

Andreas Struengmann & family (#249)

  • $ 12 B
  • Pharmaceuticals
  • Germany
  • M
  • 76 Years

About Me

Andreas Struengmann and twin brother Thomas were early backers of BioNTech, which partnered with Pfizer to make a vaccine for Covid-19. The brothers cofounded generic drugmaker Hexal in 1986 and sold it to Novartis in 2005 for some $7 billion. The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding. In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.
About Images

Achievements

Career Highlights

A snapshot of the defining milestones, leadership decisions, and breakthroughs that shaped Andreas Struengmann & family’s rise and global influence.

  • #220   Billionaires (2025)

Wealth Growth

Net Worth Growth Over Time

Tracking Andreas Struengmann & family’s net worth journey over the years, highlighting key growth phases and financial milestones.

Current Net Worth: $11.8B (February 5, 2026)